Home » Stocks » FIXX

Homology Medicines, Inc. (FIXX)

Stock Price: $6.47 USD -0.03 (-0.46%)
Updated Jul 26, 2021 9:36 AM EDT - Market open
Market Cap 371.05M
Revenue (ttm) 31.42M
Net Income (ttm) -94.44M
Shares Out 50.36M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $6.47
Previous Close $6.50
Change ($) -0.03
Change (%) -0.46%
Day's Open -
Day's Range 6.46 - 6.63
Day's Volume 13,371
52-Week Range 5.94 - 15.52

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Homology Medicines (FIXX) delivered earnings and revenue surprises of 96.92% and 3681.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End -

2 months ago - GlobeNewsWire

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

- Data From Company's PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations -

3 months ago - GlobeNewsWire

- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership -

3 months ago - GlobeNewsWire

Dilution is on the way thanks to the company's latest stock offering.

3 months ago - The Motley Fool

BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for...

3 months ago - GlobeNewsWire

BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell, subjec...

3 months ago - GlobeNewsWire

Homology Medicines (FIXX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...

4 months ago - Zacks Investment Research

Homology Medicines (FIXX) delivered earnings and revenue surprises of 4.62% and 130.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End -

4 months ago - GlobeNewsWire

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Homology Medicines Inc (NASDAQ: FIXX) has regained worldwide exclusive rights from Novartis AG (NYSE: NVS) to research, develop, manufacture, and commercialize its proprietary nuclease-free gene-editing...

Other stocks mentioned: NVS
4 months ago - Benzinga

- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication -

4 months ago - GlobeNewsWire

- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease -

5 months ago - GlobeNewsWire

Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102...

7 months ago - Seeking Alpha

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase -

8 months ago - GlobeNewsWire

Homology Medicines (FIXX) is making news on Monday after announcing a massive $60 million investment deal with Pfizer (PFE) The post Homology Medicines News: 9 Things for FIXX Stock Investors to Know Ab...

8 months ago - InvestorPlace

Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET

8 months ago - GlobeNewsWire

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

San Francisco, California--(Newsfile Corp. - October 29, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...

8 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - October 27, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...

8 months ago - Newsfile Corp

HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Show ed Improvements in Key Disease Biomarkers

9 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hom...

9 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - October 20, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inve...

9 months ago - Newsfile Corp

San Francisco, California--(Newsfile Corp. - October 16, 2020) -  Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The firm is inv...

9 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz continues its investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of in...

9 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 15, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homolo...

9 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

9 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTIONS--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

9 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of inv...

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIX...

9 months ago - Business Wire

BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual confer...

10 months ago - GlobeNewsWire

Homology Medicines (FIXX) delivered earnings and revenue surprises of 3.70% and 20.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU

11 months ago - GlobeNewsWire

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

- Executive with Extensive Rare Disease Expertise in Global Finance and  Commercial Operations -

1 year ago - GlobeNewsWire

Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

 -  Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications -

1 year ago - GlobeNewsWire

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, GTHX, IMGN, KDMN, VKTX
1 year ago - Kiplinger

- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing  for PKU -

1 year ago - GlobeNewsWire

Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for  Adults with PKU -

1 year ago - GlobeNewsWire

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the live... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Arthur Tzianabos
Employees
205
Stock Exchange
NASDAQ
Ticker Symbol
FIXX
Full Company Profile

Financial Performance

In 2020, FIXX's revenue was $2.70 million, an increase of 62.18% compared to the previous year's $1.67 million. Losses were -$128.69 million, 23.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for FIXX stock is "Strong Buy." The 12-month stock price forecast is 23.60, which is an increase of 264.76% from the latest price.

Price Target
$23.60
(264.76% upside)
Analyst Consensus: Strong Buy